Gameto

Website

Gameto, Inc.

22 Investors
Reproductive Biotechnology
Bee Cave, TX

Gameto, Inc. is a clinical-stage biotechnology company developing novel therapies for women's reproductive health by leveraging cellular engineering. The company's primary focus is on making In Vitro Fertilization (IVF) and egg freezing shorter and safer by maturing eggs outside of the body, which significantly reduces the need for extensive hormonal injections.

Products & Team

Fertilo

Infertility Cell TherapySeed

Fertilo is a therapeutic solution derived from induced pluripotent stem cells (iPSCs) that contains engineered ovarian support cells. It is designed to mature a patient's eggs outside of the body (in vitro maturation), recreating the natural process in a laboratory setting.

Value Proposition

Fertilo addresses the significant physical, emotional, and time-related burdens associated with conventional IVF and egg freezing by offering a shorter, safer, and more comfortable patient experience.

Pain Points

Patients currently face long and physically demanding hormone injection regimens, which can last 10-14 days and carry associated health risks and discomfort. Gameto's technology aims to alleviate these issues.

Matures eggs outside the body (ex vivo)Shortens the hormone injection cycle from 10-14 days to 2-3 daysReduces the hormonal burden and physical discomfort for patients
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
Bee Cave, TX
Primary headquarters

Funding History

Total Raised:
$44.0M
E

Equity Offering

Closed
July 2025
$44.0M
Raised
Progress
100%
Raised
$44.0M
Target
$44.0M
#000190162825000003